We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

DSM Biologics and Crucell Announce Licensing Agreement with Medarex

News  
Published: December 20, 2007 
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above. ✖

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

By submitting your email address, you agree to receive email communications related to Technology Networks content, products, or our partners. You may unsubscribe from these communications at any time as we respect your privacy. View our Privacy Policy for more information.
Read time: Less than a minute

DSM Biologics and Dutch biotechnology company Crucell N.V. have announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc.

Subscribe to Proteomics & Metabolomics updates for FREE and get:

  • Daily Breaking Science News
  • Tailored newsletters
  • Exclusive eBooks, infographics and online events
Subscribe Now

This license agreement allows Medarex to use the PER.C6® production platform in its antibody research. Financial details of the agreement were not disclosed.

Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter